Nu-Med Plus, Inc. (NUMD)
| Market Cap | 848.85K-72.5% |
| Revenue (ttm) | n/a |
| Net Income | -20.79K |
| EPS | 0.00 |
| Shares Out | 83.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,239 |
| Open | 0.01 |
| Previous Close | 0.01 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.01 - 0.04 |
| Beta | -2.11 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About NUMD
Nu-Med Plus, Inc., a medical device company, engages in the design, innovation, development, enhancement, and commercialization of medical devices worldwide. The company develops a nitric oxide generating formulation; a hospital bedside nitric oxide delivery system; a clinical unit for use in medical clinics and rehabilitation centers. It is also involved in the development of a mobile rechargeable device to deliver nitric oxide gas; and a nitric oxide system that can be used for research applications, as well as a mobile/portable rechargeable device to deliver inhaled nitric oxide gas. Nu-Med Plus, Inc. was incorporated in 2011 and is based in Port Jefferson, New York.
$NUMD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NUMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NUMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NUMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NUMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NUMD from public contracts
Source: USAspending.gov
NUMD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NUMD’s recent data — informational, not investment advice